FEB 27, 2019 01:30 PM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar

Comprehensive NTRK Fusion Detection, Agnostic of the Fusion Partner, for Optimal Identification of Rare Genomic Events Using TruSightTM Oncology 500

SPONSORED BY: Illumina
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Chief Medical Officer, Illumina, Inc.
    Biography
      For the past 25 years, Dr. Febbo has worked at leading institutions throughout the United States, most recently serving as CMO of Genomic Health (NASDAQ:GHDX). Prior to joining Genomic Health, Dr. Febbo served as Professor of Medicine and Urology at the University of California, San Francisco (UCSF), where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer, and his clinical practice focused on genitourinary oncology. While at UCSF, Dr. Febbo was the co-leader of the Prostate Cancer Program at the Helen Diller Family Comprehensive Cancer Center and the Program Principal Investigator of the Translational Research Program for the Alliance for Clinical Trials in Oncology.

      Dr. Febbo holds a Bachelor of Arts degree in Biology from Dartmouth College, received his M.D. degree at UCSF, and completed his internal medicine residency at the Brigham and Women's Hospital. After his fellowship in medical oncology at the Dana-Farber Cancer Institute, he was an Attending Physician in the Genitourinary Oncology Center at Dana-Farber, Instructor at Harvard Medical School, and a post-doctoral fellow in Dr. Todd Golub's laboratory at Dana-Farber, as well as the Whitehead Institute Center for Genomic Research of MIT (now the Broad Institute). In 2004, Dr. Febbo moved to Duke University Medical Center's Institute of Genome Sciences and Policy. He has been a member of the American Society for Clinical Investigation since 2009.
    • Clinical Oncology Marketing, Illumina, Inc.
      Biography
        Maude is a specialist in molecular biology applications in oncology, across technologies and platforms. Her experience includes contributing to the FDA-approval of 5 Companion Diagnostic (CDx) molecular assays, creating the global go-to-market strategy for a dozen of CDx at various stages in regulatory approval. Maude has educated pathologists and oncologists in early adoption of technologies that have changed medicine and cancer treatments in the last decade.

      Abstract:

      NTRK fusions are rare but important recent biomarkers linked to response to new TRK inhibitors. Comprehensive genomic profiling on all solid tumors permits detection of rare genomic events and in the future may enables the use of emerging treatments such as NTRK inhibitors. NTRK genes include numerous potential fusion partners, large intronic regions and G-C rich content, making accurate and comprehensive detection of NTRK fusions difficult to perform in the lab. Amongst the variable performance of NTRK fusion assays, NTRK detection from RNA using Hybrid-Capture NGS provides comprehensive and accurate fusion detection, agnostic of the fusion partner. TruSightTM Oncology 500 is the latest comprehensive genomic profiling assay from Illumina and enables optimal NTRK fusion detection. 

      Learning Objectives:

      1. Value to adopt comprehensive genomic profiling in today's oncology care.
      2. How the Illumina TruSightTM Oncology 500 comprehensive genomic profiling assay enables optimal NTRK fusion detection. 


      Show Resources
      You May Also Like
      NOV 15, 2018 10:00 AM PST
      C.E. CREDITS
      NOV 15, 2018 10:00 AM PST
      DATE:  November 15, 2018TIME:  10:00am PT, 1:00pm ET Multiplex fluorescence immunohistochemistry offers a window into the biology of human disease, enabling the ana...
      FEB 26, 2019 09:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      FEB 26, 2019 09:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      DATE:  February 26, 2019TIME:   9:00am PST, 12:00pm EST In an era of increasingly high-throughput, large-scale biology, with companies, government and non-prof...
      FEB 20, 2019 09:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      FEB 20, 2019 09:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      DATE:  February 20, 2019TIME:  9:00am PST  ...
      MAR 26, 2019 02:00 PM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      MAR 26, 2019 02:00 PM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      DATE:  March 26, 2019TIME:  2:00pm PDT, 5:00pm EDT  Prostate cancer is the second most common form of cancer in males, affecting one in eight men by the time t...
      SEP 18, 2018 02:00 PM GMT
      C.E. CREDITS
      SEP 18, 2018 02:00 PM GMT
      DATE: September 18, 2018TIME:  07:00am PDT, 2:00pm GMT Next Generation Sequencing has become an essential tool in clinical diagnostic laboratories, however this technolo...
      FEB 27, 2019 08:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      FEB 27, 2019 08:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      DATE:  February 27, 2019TIME:  8:00am PST Pluripotent stem cells (PSCs) can form any tissue or cell in the body, and are the ideal starting material to manufacture...
      Loading Comments...
      Show Resources
      Event Countdown
      • 0 Days
      • 0 Hours
      • 0 Minutes
      • 0 Seconds